Latest News
Ortho Clinical Diagnostics Announces Global Agreement to Make B·R·A·H·M·S PCT Assay Available to Ortho Customers
Jul 31, 2017
Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced a strategic relationship with B·R·A·H·M·S GmbH, part of Thermo Fisher Scientific Inc., to develop the B·R·A·H·M·S PCT (Procalcitonin) assay for use on Ortho's VITROS® Systems.
Assay plays key role in aiding clinicians in the assessment and treatment of sepsis and septic shock >
Thermo Fisher Scientific Declares Quarterly Dividend
May 18, 2017
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.15 per share.
Thermo Fisher Scientific Declares Quarterly Dividend >
Multi-Center Clinical Study Confirms Decreased Levels of Procalcitonin as an Independent Predictor of Mortality in Patients with Severe Sepsis and Septic Shock
April 20, 2017
Results from Procalcitonin MOnitoring SEpsis Study published in May 2017 issue of Critical Care Medicine
Multi-Center Clinical Study Confirms Decreased Levels of Procalcitonin as an Independent Predictor of Mortality in Patients with Severe Sepsis and Septic Shock >
Thermo Fisher Scientific Declares Quarterly Dividend
February 28, 2017
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.15 per share.
Thermo Fisher Scientific Declares Quarterly Dividend >
B·R·A·H·M·S GmbH, Teil von Thermo Fisher Scientific, gibt die Aufnahme von Copeptin in die Empfehlungen der Deutschen Gesellschaft für Kardiologie (DGK) bekannt (German)
December 06, 2016
DGK folgt den Empfehlungen der ESC Guidelines für den sofortigen Ausschluss eines akuten Myokardinfarkts (AMI) mittels Kombination aus Copeptin und Troponin; legt den Einsatz für niedergelassene Kardiologen fest.
Copeptin in den Empfehlungen der Deutschen Gesellschaft für Kardiologie (DGK) >
B·R·A·H·M·S GmbH, part of Thermo Fisher Scientific, Announces Copeptin Now Included in the German Cardiac Society (DGK) Recommendations (English translation from German press release)
Copeptin in DGK recommendations (English translation) >
Thermo Fisher Scientific Declares Quarterly Dividend
November 10, 2016
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.15 per share.
Thermo Fisher Scientific Declares Quarterly Dividend >
Thermo Fisher Scientific Joins Sepsis Alliance in Support of Sepsis Awareness Month
September 26, 2016
Thermo Fisher Scientific announces its support of the Sepsis Alliances’ Sepsis Awareness Month to drive awareness around sepsis, a complex clinical syndrome and a leading cause of death in ICUs globally.
Thermo Fisher Scientific Joins Sepsis Alliance >
Thermo Fisher Scientific Declares Quarterly Dividend and Authorizes $1.5 Billion of Share Repurchases
July 07, 2016
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.15 per share.
Thermo Fisher Scientific Declares Quarterly Dividend >
Innovative trial design helps accelerate FDA clearance process for B·R·A·H·M·S PCT license partners
July 07, 2016
An innovative trial design helped our license partners, Roche Diagnostics USA and bioMérieux, achieve FDA clearance in just 90 days for the Roche ELECSYS B·R·A·H·M·S PCT and bioMérieux VIDAS B·R·A·H·M·S PCT assays. The Procalcitonin MOnitoring SEpsis Study (MOSES) included 858 adult patients with sepsis recruited across 13 investigational sites in the U.S.
B·R·A·H·M·S PCT license partners achieve FDA clearance in 90 days >
Thermo Fisher Scientific Declares Quarterly Dividend
May 18, 2016
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has declared a quarterly cash dividend of $0.15 per share.
Thermo Fisher Scientific Declares Quarterly Dividend >
Expanded FDA clearance for B·R·A·H·M·S PCT sepsis biomarker
March 01, 2016
Thermo Fisher Scientific Inc. has received clearance from the U.S. Food and Drug Administration (FDA) that expands the clinical claims of the Thermo Scientific B·R·A·H·M·S PCT (Procalcitonin) biomarker assay for sepsis risk assessment. Clinicians can now use B·R·A·H·M·S PCT to help assess the response of septic patients to treatment by comparing a baseline PCT measurement with a PCT value taken on day four.
B·R·A·H·M·S PCT cleared for assessing mortality risk of septic patients >
Thermo Fisher Scientific Reports Record Fourth Quarter and Full Year 2015 Results
January 28, 2016
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2015.
Thermo Fisher Scientific Reports Record Fourth Quarter and Full Year 2015 Results >
New B·R·A·H·M·S PCT Testing Solution in Europe for the Samsung IB10 Point-of-Care Platform
January 25, 2016
For healthcare professionals facing the complexity of daily requirements in emergency situations, a new point-of-care test, Samsung IB B·R·A·H·M·S PCT assay, offers an integrated solution for accurate sepsis diagnosis and antibiotic stewardship. The test, which recently received a CE mark for use in Europe, may further improve medical decision-making about risk assessment and therapy management.
Read more about the Samsung IB B·R·A·H·M·S PCT biomarker assay >
